Figure 6.

Reduction of Proliferation in TIGAR-Deficient Tumor Crypt Can Be Rescued by the Addition of Malate and Nucleoside

(A) Tumor cystic organoid cultures from TIGAR^+/+Lgr5-EGFP-IRES-creER^T2/APC^fl/fl (WT) and TIGAR^−/−Lgr5-EGFP-IRES-creER^T2/APC^fl/fl (KO) small intestines after the indicated treatment for 5 days. Bar = 100 μm.

(B) Quantification (average diameter of the organoids) of (A). ^∗p < 0.05 compared to WT. ns, no significant difference.

(C) Quantification of the percentage of Ki67-positive cells in the tumor crypt cultures from WT and KO animals treated with the indicated treatments for 5 days. ^∗p < 0.05 compared to WT. ns, no significant difference.

(D) MDA staining of the tumor crypt cultures from WT and KO animals with the indicated treatments for 5 days. Scale bar, 100 μm.

(E) Size of TIGAR-deficient and control crypts following exposure to 1% oxygen (hypoxia) for 5 days. ^∗p < 0.05 compared to WT.

(F) TIGAR-deficient and control crypts were electroporated with the indicated constructs and then cultured for 5 days. Crypts expressing comparable levels of each protein, as visualized by FLAG staining, were measured for size. ^∗p < 0.05 compared to KO with Ctr-FLAG. Data are represented as mean ± SEM (n = 3).

See also Figure S6.